Galectin-3 inhibitor GB0139 protects against acute lung injury by inhibiting neutrophil recruitment and activation
Abstract
Rationale:Galectin-3 (Gal-3) drives fibrosis during chronic lung injury, however, its role in acute lung injury (ALI) remains unknown. Effective pharmacological therapies available for ALI are limited; identifying novel concepts in treatment is essential. GB0139 is a Gal-3 inhibitor currently under clinical investigation for the treatment of idiopathic pulmonary fibrosis. We investigate the role of Gal-3 in ALI and evaluate whether its inhibition with GB0139 offers a protective role. The effect of GB0139 on ALI was exploredin vivoandin vitro.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Aug 08, 2022
- Source ID
- 10.3389/fphar.2022.949264
Entities
People
- Adriano G. Rossi
- Alison C. Mackinnon
- Anders Pedersen
- Brian J. Mchugh
- Cecilia Boz
- Duncan C. Humphries
- Hakon Leffler
- Hans T. Schambye
- Nikhil Hirani
- Robert J. Slack
- Ross Mills
- Tariq Sethi
- Ulf J. Nilsson
- Wei Wang
Organizations
- United States Department of Defense